Angiotensin-converting enzyme DD polymorphism is associated with poor coronary collateral circulation in patients

Koksal Ceyhan1, Hasan Kadi, Atac Celik

  • 1Department of Cardiology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey. kceyhan09@yahoo.com

Insights

The angiotensin-converting enzyme (ACE) DD polymorphism is linked to poor coronary collateral circulation (CCC). Individuals with the D allele may experience endothelial dysfunction and higher ACE levels, impacting cardiovascular health.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetics of Coronary Artery Disease

Background:

  • The association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism and cardiovascular diseases is established.
  • However, the relationship between ACE I/D polymorphism and coronary collateral circulation (CCC) remains uninvestigated.

Purpose of the Study:

  • To explore the potential association between the ACE I/D polymorphism and the development of coronary collateral circulation (CCC).

Main Methods:

  • 113 patients with at least one totally occluded coronary artery underwent coronary angiography.
  • Coronary collateral circulation was assessed using the Rentrop classification (poor CCC: grades 0-1; good CCC: grades 2-3).
  • ACE gene polymorphism was determined using real-time polymerase chain reaction and melting curve analysis.

Main Results:

  • The ACE DD genotype and D allele frequency were significantly higher in patients with poor CCC compared to those with good CCC (P < 0.001).
  • Plasma ACE levels were also elevated in the poor CCC group (P < 0.001).
  • Independent determinants of poor CCC included left circumflex artery occlusion, ACE DD genotype, diabetes, and pulse pressure.

Conclusions:

  • The study demonstrates a significant association between the ACE DD polymorphism and poor coronary collateral circulation (CCC).
  • Poor CCC in individuals with the D allele may be attributed to endothelial dysfunction and increased plasma ACE levels.
  • This finding highlights the genetic influence of ACE I/D polymorphism on collateral development in coronary artery disease.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...